Our results demonstrated that ovarian cancer cells with elevated PABPC3 expression exhibited decreased drug sensitivity to chemotherapeutic agents and decreased sensitivity to PARP inhibitors. The gene discussed is PABPC3; the disease is ovarian cancer.